Semax & Selank vs Cagrilintide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Semax & Selank
A nootropic combination pairing two Russian-developed peptides for cognitive enhancement. Semax provides stimulating focus and neuroprotection while Selank offers anxiolytic and mood-stabilizing effects, creating a balanced cognitive enhancement stack.
Full details →Cagrilintide
Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.
Full details →Side-by-Side Comparison
| Aspect | Semax & Selank | Cagrilintide |
|---|---|---|
| Mechanism | Semax enhances BDNF expression and modulates dopamine and serotonin systems for improved focus, memory, and neuroprotection. Selank affects BDNF and GABA systems, providing anxiolytic effects and immune modulation. Together they support cognitive function while managing stress and anxiety. | Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1. |
| Typical Dosage | Semax: 200-600mcg intranasally 2-3 times daily. Selank: 250-500mcg intranasally 2-3 times daily. Can be used together or alternated based on needs. | Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined. |
| Administration | Primarily administered intranasally for rapid brain uptake. N-Acetyl versions (NA-Semax, NA-Selank) offer enhanced stability and potency. Can also be injected subcutaneously. | Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved. |
| Side Effects | Semax may cause mild irritability or hair shedding. Selank may cause mild fatigue or nasal irritation. Both are generally well-tolerated. | Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially. |
| Best For |